The GLP-1 Drugs Are Making People Eat Less of Everything — What Food Companies Are Doing About It

Ozempic users eat significantly less. With millions on GLP-1 drugs, food companies are reformulating products for smaller servings. Here is the specific business transformation happening.

The business implication of GLP-1 drugs that the food industry is quietly confronting is not subtle: approximately 10-15 million Americans are currently taking GLP-1 drugs, eating significantly less than before, and the number is growing. The specific eating pattern changes that GLP-1 users report — smaller portions, reduced appetite for ultra-processed foods, less interest in snacking, greater preference for protein — are changes whose aggregate effect on food company revenues is beginning to appear in quarterly earnings discussions.

Convenience food companies whose products are predominantly snack foods, candy, and sugary beverages have seen the earliest indicators. Kraft Heinz, Nestle, and other major food companies have explicitly mentioned GLP-1 drug prevalence in investor communications as a demand-side factor to monitor. The specific foods that GLP-1 users most frequently report reduced appetite for — high-fat, high-sugar, ultra-processed snack products — are among the highest-margin items in these companies' portfolios.

The food industry's adaptation strategy is developing in two directions. First: smaller portion reformulation. Companies are accelerating the development and marketing of smaller-serving products — not just smaller bags but food products designed to deliver satisfaction in fewer calories and smaller quantities for consumers whose appetite regulation has changed. Second: nutritional density improvement. Kerry's 2026 health and nutrition trends analysis explicitly identifies GLP-1 drug prevalence as a driver of demand for 'nutrient-dense' foods — products that deliver high nutritional value in small portions, meeting the specific needs of consumers whose caloric intake has declined but whose nutritional requirements haven't.

The restaurant industry is experiencing analogous pressure. Quick service restaurants are reporting reduced average check sizes from identified GLP-1 user customers. The 'kids menu' portions that were previously associated with children are being ordered by adults on GLP-1 drugs who find standard restaurant portions excessive. Menu reformulation toward higher-protein, smaller-portion items is the industry's primary adaptation response.

For investors: the food sector's GLP-1 exposure analysis has become a standard element of analyst coverage. Companies with high snack food concentration are seen as most exposed; companies with high protein food, functional food, and convenience fresh food concentration are seen as most positively positioned.